Overview

HEALEY ALS Platform Trial - Regimen G DNL343

Status:
Not yet recruiting

Trial end date:
2025-08-01

Target enrollment:

Participant gender:

Summary

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen G will evaluate the safety and efficacy of a single study drug, DNL343, in participants with ALS.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Merit E. Cudkowicz, MD

Collaborator:

Denali Therapeutics Inc.